New agents for chemoprevention of prostate cancer.
The magnitude of the problem of prostate cancer, and the failure of conventional chemotherapy and surgery to effect a marked diminution in the total number of deaths from this disease, now indicate that chemoprevention of prostatic carcinogenesis must be seriously considered. We describe the development of a new system for quantitating the process of prostatic carcinogenesis in an experimental animal, and the use of this system to demonstrate that the retinoid, 4-hydroxyphenylretinamide, the deltanoid, Ro24-5531, and the estrogen analog, tamoxifen, all are effective agents for prevention of experimental prostate cancer.
D000818:Animals; D016588:Anticarcinogenic Agents / Q000008:administration & dosage*; D002117:Calcitriol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004195:Disease Models, Animal; D015507:Drugs, Investigational / Q000627:therapeutic use*; D017313:Fenretinide / Q000494:pharmacology*; D008297:Male; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000517:prevention & control*; D051381:Rats; D013629:Tamoxifen / Q000008:administration & dosage*; D016896:Treatment Outcome